ResMed shares have been caught up in the recent market volatility. Has this created a buying window for ResMed shares?

Let's see what the broker is saying about these healthcare stocks. The post Trump 2.0: Macquarie's take on the winners and ...

Shares of ResMed Inc. RMD advanced 5.82% to $216.44 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to 5,456.90 and ...

From Regal’s Phil King, who says stocks are nearing their bottom, to Airlie’s Emma Fisher, buying US-exposed equities, here ...

Shares of ResMed Inc. RMD slipped 3.97% to $204.54 Tuesday, on what proved to be an all-around poor trading session for the ...

In a welcome move, ResMed saw its Relative Strength Rating rise from 65 to 78 on Tuesday. Please watch the video at Investors ...

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

If I had $10,000 to invest in the market today, I'd be looking for high-quality businesses that have fallen with the broader ...

Professional networking site LinkedIn has put together its annual list of Australia's best workplaces for career growth ...

SAN DIEGO – Resmed has announced that its home sleep apnea test, NightOwl, is now available across the U.S.

Post Liberation Day, life science companies are clarifying the likely impact of Trump's tariffs – and the news is largely positive.

StockNews.com downgraded shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday morning. A number of other equities research ...